

INDEX

- α_2 -acid glycoprotein, 439
- 5-fluorouracil, 979
- 5-fluorouracil, 988–989
- 5-FU, 855
- Absorption of drugs, 431–433
- Absorption routes, 254–255
- Acceptance criteria for in vitro-in vivo correlation, 485
- Accuracy and precision, 190
- ACE inhibitors, 71–73
- Acetaminophen, 940
- Active metabolites, 760–761, 840–841, 938–940
- Active transport, 252–253, 290
- ACYL glucuronides, 840
- Adeno-associated virus, 375–337
- ADME, 118, 408–410
- ADMET, 977
- Adverse Drug Reactions (ADRs), 776
- AIDS, 1277
- Albumin, 438–439
- Allometric scaling, 1048
- Allometry in pharmacokinetics, 1010–1012
- All-trans-retinoic acid, 1213–1216
- Animal models, 1088–1089
- Antibiotics, 1272
- API, 152
- Artifactual sources of atypical kinetics, 710–711
- Astrocytes, 362
- Azole antifungal agents, 896
- Batch failure rate, 121–122
- Biliary clearance, 733
- Bile, 1116
- Bioavailability, 250
- Bioinformatics, 25–28
- Bioinformatics resources, 26
- Biologics, 1272–1274
- Biopharmaceutics Classification System (BCS), 231
- Biophase model, 1148–1151
- Biotechnology products, 1281–1285
- Biowaivers for changes in the manufacture of a drug product, 530
- Biphasic kinetics, 704
- Blood Brain Barrier (BBB), 354, 436
- Blood Compartment, 1180–1181
- Blood perfusion, 435
- Blood-Cerebrospinal Fluid Barrier (BCSFB), 356–357
- Blood-CSR barrier, 436

- Bodily fluids, 1066–1067
Botanical drug products, 1295
Boxenbaum, 1011
Brain Efflux Index (BEI), 367
Breast Cancer Resistance Protein (BCRP), 888
Buccal adhesive delivery devices, 602
Buccal, 262–263, 601–603
Buffers, 559–561
Burger and Ramburger rules, 475
- Caco-2
Caco-2 cells, 888
CADD, 77
Cancer informatics, 36–38
Capillary Electrophoresis (CE), 183–184
Capsules, 597
Carbohydrates, 257
Carcinogenicity, 1284
Carcinogenicity studies, 1299
Carrier mediated, 252–253
Case of multiple substrates, 700
Cellular therapies, 1287, 1288–1289
Cellulose derivatives, 490
Cervastatin, 778
Characterization of CYP enzymes, 629
Chemical stability, 547, 551
Chemoinformatics, 22–25
Chiral Methods, 184–185
Chitosan, 267, 302–305, 592–594
Chromatic separation, 126
Chromatographic methods, 234
Clinically significant drug interactions, 904–906
Cocrystals, 457–459
CoMFA (comparative molecular field analysis), 13–14
Compartmental analysis, 1046–1047
Compassionate use, 1290–1291
Compression force, 503–504
Computational biology, 8–10
Computational drug development, 3–8
Computer-Aided Drug Design (CADD), 2, 48
Conformational analysis, 6–8
Control animal samples, 123–124
Controlled release pharmaceuticals, 598
Coprocesed diluents, 492
Coprocesed lactose, 491
Counterion, 460–462
Cremophor EL, 591–592
Crystal form, 292
Crystalline forms, 456
Crystallization, 475–477
CTC/X, 1270
Cutaneous administration, 432
Cyclodextrins, 594–595
Cyclosporin, 856
CYP content in various human and rat organs, 631
CYP enzymes, 628
CYP inhibitors, 650–652
CYP inhibitory potential, 865–869
CYP isoforms, 857
CYP substrates, 635–644
CYP1 family, 653
CYP2 family, 653–664
CYP4 family, 668–669
CYP450, 34
Cytosol, 860
- DART, 1278
Degradation, 295–296
Dendrimers, 589
Derivatization, 160–162
Derivatizing Agents, 968
Dermal administration, 1084–1085
Dermal formulations, 605–606
Desirable characteristics of a dosing formulation, 575
Determination of mass, 212–213
Diclofenac, 949
Diffusion cells, 240–241, 309–311
Digoxin, 885
Diluents, 484–489
Disintegrants, 494–496
Dissociation constant, 293–294
Dissolution rate of drugs, 501
Dissolution rate test apparatus, 507
Distribution/Transport, 1187–1192
DMPK, 1171
Dosage form development, 485
Dosing Vehicles, 130–131
Drug absorption, 289–291
Drug Distribution, 323–324
Drug interactions with herbs and natural food products, 901–906
Drug metabolizing enzymes in liver of different species, 526
Drug permeation, 269–271
Drug transport across the BBB, 377–379
Drug-drug interactions, 777–785, 889–894, 1050–1051

- Drug-drug interactions with
 - benzodiazepines, 895–901
- Drug-receptor binding, 1136–1138
- Drying process, 502–503

- Ear formulations, 608
- Ester and amide prodrugs, 838
- Echinacea, 880, 905
- Effect of disease on drug clearance, 739–741
- Efflux transport, 290
- Electrochemical (EC) detector, 181
- Elimination half-life, 1045–1046
- EMA, 926
- Emulsions, 596
- Encapsulation, 344–346
- Endocytosis, 254
- Enteral routes, 255–264
- Enzyme induction potential, 869–871
- European Union, 1301
- Everted intestinal segments, 240
- Excipients, 589–595
- Excretion processes, 295–296
- Expired air, 1116
- Exploratory data analysis, 517
- Extent of distribution, 331–335
- External sources of information, 56
- Eye drops, 432

- Facilitated diffusion, 252, 290
- Factors influencing renal clearance, 727–728
- Fatal interactions with coadministered drugs, 855
- Fc receptors, 444
- FDA, 926
- FDA guidelines, 1074
- Felbamate, 940
- Fibronectin, 94
- Filtration, 157
- Flavin-containing monooxygenases (FMOs), 862
- Formulation, 484–502
- Full scan mass spectrometry, 955–956

- Gallbladder, 287
- Gamma isotopes, 168–169
- Garlic, 904, 905
- Gastric emptying, 294
- Gastric emptying rates, 261
- Gastric emptying time, 525
- Gastrointestinal secretions, 256

- GC derivatizing agents, 162
- Gemfibrozil, 855
- Gene therapies, 374, 581–587, 1287–1288
- Gene therapy products, 1285–1289
- General case safety evaluation requirements, 1269
- Generic PBPK models, 1223–1206
- Genetic polymorphism, 633–635
- Genetic toxicity assessment, 1281
- Ginko biloba, 880, 903, 904
- Ginseng, 880
- Glucuronidation, 830
- Granulating solvent, 502
- Granulation procedure, 502–503
- Guinea pigs, 993

- Henderson-Hasselbalch equation, 252
- Hepatic clearance, 728–738, 1018–1019
- Hepatic elimination, 717
- Hepatocytes, 858
- High Performance Liquid Chromatography (HPLC), 176–183
- High Throughput Screening (HTS), 313
- Hill equation, 1142–1144
- Homology modeling, 9–10
- HQSAR(hologram quantitative structure-activity relationships), 57–65
- HT29 cell model, 237–238
- Human enzyme inducers, 869
- Human hepatic drug-metabolizing CYP enzymes, 754
- Human liver microsomes, 859
- Hydrogen bonding, 234, 260
- Hydrogen bonding property, 230

- ICH, 1296
- ICH guidelines, 1074
- Ideal body mass range, 1016
- Immortalized cell lines, 996
- Immunoinformatics, 32–34
- Impact of drug measurement on study design, 1062–1063
- Improving stability, 563–564
- In silico, 34, 834, 997–998
- In situ brain perfusion techniques, 367–368
- In vitro-in vivo extrapolation, 766
- In vivo metabolism of prodrugs, 838–839
- IND, 1075
- INDA, 1269
- Indirect response models, 1152–1156
- IND-targeted toxicology studies, 1076–1077

- Inducers of human CYP enzymes, 670
Induction potential for drug-metabolizing enzymes, 861
Inductive drug-drug interactions, 860
Infrared (IR), 163–164
Inhalation administration, 1085
Inhalation formulations, 608–609
Inhibitors of protein-protein interactions, 102–110
Inhibitory drug-drug interaction, 860
Inhibitory potential for drug-metabolizing enzymes, 861
Installation qualification (IQ), 186
Insulin receptor, 382–383
InteliSite capsule, 242
Interleukin-11 (IL-11) 1242–1245
Interspecies differences in drug bioavailability, 523
Intestinal cell cultures, 311–313
Intestinal membrane, 288–289
Intestinal paracellular enhancers, 300–308
Intestinal paracellular pathway, 298–300
Intestinal pH values, 259
Intracerebral microdialysis, 369
Intracerebral ventricular, 372
Intradermal, 272
Intrahepatocellular transport, 732
Intramuscular injection, 433
Intramuscular, 273
Intrathecal injection, 433
Intravenous (IV) administration, 1083
Intravenous injection, 433
Intravenous, 598–599
Ion trap, 962–964
Ionic strength, 515
Irreversible effects, 1158–1162
Isoform-specific inhibitors, 865
Isolation and Identification of Metabolites, 831–833
Isothermal kinetics, 562–563
Isotope assays, 166–167

Japan, 1302–1304

Kava-kava, 880
Kinetics, 552–561, 889–894

Labrasol, 1082
Lactose, 489
Large intestine, 286–287
LC/NMR, 965–966
LC-MS/MS, 119
Lead identification, 1207–1208
Levy's direct effect model, 1146
Ligand-binding assay technology, 135
Ligand-binding assays, 164–166
Limit of detection (LOD), 190
Limit of quantification (LOQ), 190, 1062
Linkage between drug metabolite and toxicity, 978
Lipid solubility, 331
Lipinski's rule of five, 235–236
Lipophilicity, 215–216, 229–230, 260, 292
Lipophilicity: log P and log D, 232–233
Lipoproteins, 439
Liposomal partitioning, 233
Liposomes, 589
Liquid scintillation counting, 1119
Liquid-Liquid Extraction, (LLE), 157–158
Liver, 287
Liver postmitochondrial supernatant, 859
LRP1 and LRP2 receptors, 383–384
Lubricants, 493–494

Macrophages, 444
Madin-Darby Canine Kidney (MDCK), 237
Magnetic resonance techniques, 369–370
Major human hepatic CYP enzymes, 649
Mammalian anatomy as it relates to drug metabolite, 944
Mass analyzers, 954–965
Mass balance calculation, 1123–1124
Mass balance study, 1104, 1105
Mass spectrometer detector, 181–183
Mass spectrometry, 952–965
Material Safety Data Sheet (MSDS), 154
Matrix effects, 129–130
Mechanism-based inhibition, 798–800
Mechanisms of adverse drug-drug interactions, 854–855
Mechanisms of cytochrome P450 inhibition, 781–785
Mechanisms of renal clearance, 721–724
Medium Chain Fatty Acids (MCFAs), 301–302
Membrane permeability, 434–435
Metabolic interactions, 882–884
Metabolic phenotyping, 861
Metabolic profiling, 1125–1126
Metabolic stability, 930, 1108–1109
Metabolic stability of prodrugs, 839

- Metabolism/elimination, 1181–1182
 Metabolism informatics, 35
 Metabolism, 830
 Metabolite compartments, 1182–1183
 Method validation, 198–199
 Method development strategy, 125–129
 Methotrexate, 1211–1213
 Mibefradil, 855
 Micelles, 587–588
 Michaelis-Menton equation, 698–700, 701
 Microcrystalline cellulose, 491–493
 Micronization, 587–589
 Microparticulate bioadhesive systems, 603
 Molecular docking, 18–20
 Molecular size, 230, 234
 Molecular Weight (MW), 260, 331
 Monamine Oxidase (MAO), 862
 Mucosa, 283
 Multiple intravenous doses, 1312
 Musciliary clearance, 265
 Muscularis externa, 283
- Nanoparticles, 587–589
 Nasal, 266–267, 600–601
 Nasal sprays, 432
 NDA-targeted nonclinical development, 1092–1096
 Neuroinformatics tools and databases, 31
 Neutron Activation Analysis (NAA), 169–170
 Nitric oxide donors, 307–308
 Nomenclature of CYP enzymes, 631–633
 Noncompartmental modeling, 1170–1171
 Nonhuman primates, 992
 Nonisothermal kinetics, 563
 Nonlinear pharmacokinetics, 1049–1050
 Nonneuronal efflux transporters, 884–886
 Nonpolar surface area, 260
 Nonrodent mammalian models, 992
 Nonseparation methods, 162–172
 Novel cytokine therapy, 1241–1242
- Ocular formulations, 606–608
 Oncogenesis, 89–95
 Operational Qualification (OQ), 186–187
 Ophthalmic, 267–268
 Optical isomers, 1291–1292
 Optimal species for scale-up to human, 1016–1017
 Oral, 255
 Oral administration, 431
 Oral bioavailability, 1043–1044
 Oral contraceptives, 1289–1290
 Oral formulations, 596–598
 Orphan drugs, 1294–1295
 Other routes of elimination, 717
- P450 (CYP), 776
 P450 inhibition, 872–873
 P450 phenotyping, 863–865
 Pancreas, 287
 Paracellular pathway, 290–291
 Paracellular transport, 229
 Parenteral routes, 272–274
 Parenteral therapy, 599
 Particle size, 292
 Passive diffusion, 251–252, 264, 290
 Paste, 597
 Pathogen-host interaction, 95
 Pathophysiology, 1238–1240
 Pediatric and geriatric claims, 1292–1294
 PEG conjugates, 342
 Pegylation, 341–342
 Peptidomimetic inhibitors, 103–106
 Percipitation, 157
 Preferred and acceptable P450
 Performance Qualification (PQ), 187–188
 Perfusion-limited distribution, 329–331
 Permeability, 228
 Permeability-limited distribution, 328–329
 P-glycoprotein, 885
 P-glycoprotein substrates, 336
 P-gp inhibitor, 365
 pH partition (pK_a), 231
 Pharmaceutical excipients, 152
 Pharmacodynamics, 1135
 Pharmacoenhancement, 886–887
 Pharmacogenetics, 988–989
 Pharmacokinetic analysis, 1314–1322
 Pharmacokinetic clinical studies, 897–898
 Pharmacokinetic/pharmacodynamic integration, 898–901
 Pharmacokinetics and pharmacodynamics, 1164
 Pharmacophore mapping, 15–16
 Phase I, 1258–1261
 Phase I functionalization, 830
 Phase I oxidation, 856
 Phase I reactions, 946, 962–985
 Phase I and II drug metabolizing enzymes, 945
 Phase I and II reactions, 982
 Phase II conjugation, 830
 Phase II oxidation, 856

- Phase II reactions, 946, 985–987
Phase III, 1277
Physical stability, 547–548, 548–551
Physiological parameters in different species, 524
Placental barrier, 437
Plasma protein binding, 881
Polar solutes, 292
Polar Surface Area (PSA), 234–235, 260
Polyethylene imine (PEI), 583
Polymer characteristics, 496
Polymer-diluent interaction, 499
Polymer-drug interaction, 499
Polymer-excipient interaction, 499–500
Polymorph screen, 469–475
Polymorphic drug metabolism, 1052–1053
Polymorphism, 338–339
Polypharmacy, 990
Poor linearity, 132
Positron Emission Tomography (PET), 368
Positron isotopes, 167–168
Powders, 597
Preparation of liver microsomes, 927–928
Primary transporters, 335–336
Probe substrate selection, 790–792
Prodrug design, 339–340
Protein binding, 332–335, 1083
Protein precipitation (PPT), 127
Protein/peptide formulations, 580–581
Pulmonary elimination, 717
Purity, 214–215
- QSAR, 60, 65–69
Quadrupole linear ion trap, 964
Quantitative Autoradiography (QAR), 368–369
Quantitative Structure Activity Relationship (QSAR), 10–15
- Radioactive isotopes, 171
Radioisotopes employed in preclinical mass balance studies, 1107
Radiometric detector, 181
Rate of distribution, 327–331, 434–435
Rational drug design, 2
Recombinant P450 isoforms (rCYP), 859–860
Rectal, 263–264, 604
Rectal administration, 432
Refractive Index Detector (RID), 181
- Regulation of CYP enzyme expression, 669–672
Regulation of herbal supplements, 902
Relationship between pharmacokinetics and pharmacodynamics, 1135
Relative humidity, 561
Release modifiers, 496–500
Renal clearance, 720–728, 1019–1020
Renal elimination, 716–717
Reversible inhibitors, 800–807
Rodent models, 992–994
Routes of drug elimination, 716–720
Rule of exponents, 1023–1024
Rule of Five (ROF), 413–414
- SAD, 125
Safety margins, 1073, 1078–1079
Safety pharmacology, 1304–1305
Safety testing of metabolites, 941
Salt/cocrystal formulation, 462–464
SALTS, 457–459
Sample collection, 1114–1119
Sample preparation, 155–162
Sampling times, 1063–1066
Sampling, 153–155
Scaling half-life, 1029–1030
Selective serotonin reuptake inhibitors, 882
Separation methods, 172–184
Serosa, 283
Short-range interactions between biomolecules, 88
Significant DDI, 813
Single intravenous dose, 1310–1311
Single oral dose, 1312
siRNA, 420
Skin physiology, 269
Small intestine, 284–286
Solid-Phase Extraction (SPE), 158–160
Solubility, 215–216, 231, 291–292
Solution stability, 547–548
Solutions, 596
Species considerations, 752
Species differences in bioavailability, 1089–1091
Species for which microsomes and hepatocytes are commercially available, 932
Specificity, 190
SSRIs, 896
St. Johns wort, 856, 904, 905

- Stability, 216
- Stable isotope analysis, 171–172
- Stomach, 283–284
- Storage compartments, 1178–1180
- Structure elucidation, 213–214
- Structure-Activity relationship, 99–100
- Subcutaneous, 272
- Subcutaneous injection, 433
- Sublingual Administration, 431–432
- Sublingual, 262–263
- Submucosa, 283
- Substrate inhibition, 706–708
- Substrate-based modeling, 412–413
- Sugars, 490
- Surfactants, 505
- Suspensions, 596–597
- Synthesis of metabolites, 833–834
- Synthetic contaminants, 152
- Systemic availability, 250
- Systemic clearance, 1039–1043

- Tables, 598
- Target tissues, 1183
- Temperature, 556–557
- Terfenadine, 855
- Therapeutic index, 999
- Thiolated polymers, 306
- Thiopurine, 989
- Thrombocytopenia, 1238–1242
- Thrombopoiesis, 1233–1238
- Thrombopoietin (TPO), 1245

- Tight junctions (TJs), 298
- Tolerance models, 1162
- Total body clearance, 1020
- Toxicoinformatics, 35–36
- Toxicologically active metabolites, 940
- Transdermal, 268–269, 603–604
- Transduction models, 1156–1158
- Transfollicular route, 269
- Transgenic animals, 420
- Transporter interactions in the ADME process, 416
- Transpulmonary, 264–265
- Triple quadrupole, 954–955
- Tubular reabsorption, 723–724
- Tubular secretion, 722–723

- Unstirred Water Layer (UWL), 260–262
- Uptake Routes, 1183–1187

- Vaginal, 271–272, 605
- Vehicles, 589–595
- Volume of distribution, 326–327, 439–440, 1027–1029, 1044–1045

- Wet/dry granulation, 502

- Xenobiotic Metabolizing Enzymes (XMEs), 920, 931
- X-Ray Powder Diffraction (WRPD), 464

- Zonula Occludens Toxin (Zot), 305–306